Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice.

Stephen J Greene^1,2, Alexander Michel³, Coralie Lecomte⁴, Paolo Manca⁵, Katsiaryna Holl⁶, Michele Senni⁷

¹Division of Cardiology, Duke University Medical Center/Duke Clinical Research Institute, Durham, USA.

²Duke Clinical Research Institute, Durham, NC, USA.

³Real World Evidence Centre of Excellence, Bayer Consumer Care AG, Basel, Switzerland.

⁴Science, Aetion, a Datavant company, New York, USA.

⁵Medical Department, Bayer S.p.A., Milano, Italy.

⁶Global Medical & Evidence Cardiology, Bayer AG, Berlin, Germany.

⁷Cardiovascular Department and Cardiology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.

PubMed PMC DOI PDF

Abstract

STUDY OBJECTIVE: To evaluate the following among new users of vericiguat: up-titration patterns, factors associated with up-titration, occurrence of hypotension/syncope, predictors of hypotension/syncope. DESIGN: Retrospective cohort study (linked claims and electronic health record data). SETTING: US clinical practice. PARTICIPANTS: 1361 new users of vericiguat. INTERVENTIONS: N/A. MAIN OUTC…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.